Navigation Links
NicOx' Naproxcinod ABPM Data Presented at American Heart Association
Date:11/7/2007

SOPHIA ANTIPOLIS, France, Nov. 7 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that clinical results of an exploratory pharmacodynamic study for naproxcinod using Ambulatory Blood Pressure Monitoring (ABPM) were presented yesterday at the American Heart Association Scientific Sessions 2007, in Orlando, Florida. Naproxcinod is the first compound in the COX-Inhibiting Nitric Oxide Donator class of anti-inflammatory agents and is in clinical development for the treatment of the signs and symptoms of osteoarthritis. This ABPM study was designed to provide complementary blood pressure data to the ongoing phase 3 program. The data presented at the AHA showed that the blood pressure measurements for naproxcinod over 24 hours were consistently below those observed for naproxen, a currently marketed non-steroidal anti-inflammatory agent (NSAID). NSAIDs are known to have the detrimental effect of raising patients' blood pressure. The top-line results of this trial (the 104 study) were announced last December (see press release of December 8, 2006).

The presentation included line graphs displaying the hourly mean blood pressure measurements over 24 hours following a two week treatment period, during which naproxcinod or naproxen were administered twice daily. These graphs showed that the hourly systolic blood pressure (SBP) and diastolic blood pressure (DBP) values for naproxcinod were consistently below those observed in the naproxen group (see NOTE 1). In addition, the data suggest that the blood pressure effect of naproxcinod lasts for 7 to 8 hours after each administration.

Considering the average of the ABPM measurements over 24 hours the results showed an almost 2 mmHg reduction in SBP and DBP for naproxcinod compared to naproxen, in terms of the mean change from baseline, after a 2 week active treatment period. This difference did not reach statistical significance for SBP (p=0.101), the primary endpoint of the study, but did ac
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  HealthLoop® released an app version of its doctor-patient ... and allows people to share medical device and activity ... technologies to enhance the HealthLoop experience for iPhone users, ... doctors between visits. "This new flood ... is exciting," says HealthLoop founder Dr. Jordan Shlain ...
(Date:9/30/2014)... VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... tissue diagnostics market, Frost & Sullivan recognizes Ventana ... Roche Group, with the 2014 North American Frost ... to strict quality practices along with a focus ... Ventana a global leader in tissue-based cancer diagnostic ...
(Date:9/30/2014)... 2014  Georgia-Pacific Professional is a leading provider ... a wide range of away from home applications. ... in healthcare, including hospitals, long-term care facilities, surgical ... its healthcare products and solutions to the dental ... of infection control in the dental office," said ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... Mass., Nov. 11, 2010 Interleukin Genetics, Inc. (OTCQB: ILIU) ... ended September 30, 2010. Revenue for the three ... $0.3 million for the same period in the prior year. ... as we experience positive growth. Research and development ...
... NEW YORK, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- American ... ("the Company" or "AOBO"), a pharmaceutical company dedicated ... commercialization of a broad range of prescription and ... of AOBO Wujia Rongxue Oral Liquid, ("AWRO Liquid"), ...
Cached Medicine Technology:Interleukin Genetics Reports Third Quarter 2010 Financial Results 2Interleukin Genetics Reports Third Quarter 2010 Financial Results 3Interleukin Genetics Reports Third Quarter 2010 Financial Results 4Interleukin Genetics Reports Third Quarter 2010 Financial Results 5American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... to improve breast cancer risk prediction and to ... a study published in Breast Cancer Research (BCR ... density and breast cancer risk: a case-control study ... strong connection between breast density and breast cancer ...
(Date:9/30/2014)... partners successfully established a visual mapping of the ... suppressor cells (MDSC). The damage and immune suppression ... this is a major stepping stone in creating ... factors from precursors present in hematopoietic organs such ... population of cells suppresses the activity of various ...
(Date:9/30/2014)... University of Eastern Finland shows that dietary polyunsaturated fatty ... The sources of polyunsaturated fatty acids include fish, vegetable ... Arteriosclerosis, Thrombosis & Vascular Biology , an esteemed journal ... not found an association between the consumption of saturated ... that the mere reduction of saturated fats from the ...
(Date:9/30/2014)... This two-day, advanced PT continuing education course ... may arise following a concussion or mild traumatic brain ... from sports related injuries, car accidents, falls, to the ... of returning soldiers from war zone regions. While at ... can result in similar injuries, the course will emphasize ...
(Date:9/30/2014)... By Dennis Thompson ... -- Every day, people receive medical implants -- artificial ... may not have been rigorously tested before or after their ... studies contend. The studies -- conducted by prominent nonprofit ... Medicine -- lay the blame for inadequate medical device ...
Breaking Medicine News(10 mins):Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:Dietary polyunsaturated fatty acids linked to smaller risk of coronary heart disease 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4
... these patients, researcher says , , FRIDAY, Oct. 10 (HealthDay ... 75 percent higher risk for developing colorectal cancer sometime ... syndrome is a conglomeration of three or four diseases, ... illnesses, including a number of cancers," said study co-author ...
... excellence in the implementation of electronic health records (EHRs), the ... of the 2008 Davies Awards in the Organizational, Ambulatory and ... ... Chicago, IL (PRWEB) October 10, 2008 -- Honoring excellence in ...
... Mich.---The University of Michigan received $5 million from the ... resource of high-quality experimental data sets of drug-making compounds ... new level. , The resource will house the ... the effectiveness of potential new drugs, said Heather Carlson, ...
... 10 The Johns Hopkins University School,of Medicine ... Breast Cancer Strategies: From Biomarkers to Treatment,Selection," to ... advances in,breast cancer treatment., In recent years, ... to chemotherapeutic and biologic treatment combinations that are,increasingly ...
... Mobile Massage Team, (http://www.mobilemassageteam.com ), a leading ... wellness programs, promotional events, and special,affairs, announced ... area throughout,eastern Pennsylvania and the greater Philadelphia ... about the increasing interest in our on-site,seated, ...
... nationally recognized faculty will,present the very latest treatment ... course "Optimizing Adjuvant Breast Cancer,Strategies: From Biomarkers to ... It is challenging for practicing oncologists and other ... on the latest patient care,advances. This accredited course ...
Cached Medicine News:Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... The VITROS HBsAg assay is ... by the U.S. Food and ... in a random,access format on ... Intellicheck. Now you can run ...
... The Total PSA method for ... immunoassay module is an in vitro ... total prostate specific antigen (TPSA) in ... used as an aid in the ...
... based on sequential binding of HCG from ... for the *-chain of HCG) immobilized on ... the *-chain of HCG) conjugated to the ... chromogenic substrate is added and colors developed. ...
Medicine Products: